ES2111973T3 - La diagnosis, la evaluacion, y el tratamiento de la enfermedad de la arteria coronaria mediante simulacion del ejercicio por la utilizacion de la administracion en ciclo cerrado de farmacos de un agente beta agonista que simula el ejercicio. - Google Patents

La diagnosis, la evaluacion, y el tratamiento de la enfermedad de la arteria coronaria mediante simulacion del ejercicio por la utilizacion de la administracion en ciclo cerrado de farmacos de un agente beta agonista que simula el ejercicio.

Info

Publication number
ES2111973T3
ES2111973T3 ES95101920T ES95101920T ES2111973T3 ES 2111973 T3 ES2111973 T3 ES 2111973T3 ES 95101920 T ES95101920 T ES 95101920T ES 95101920 T ES95101920 T ES 95101920T ES 2111973 T3 ES2111973 T3 ES 2111973T3
Authority
ES
Spain
Prior art keywords
exercise
diagnosis
evaluation
treatment
simulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95101920T
Other languages
English (en)
Inventor
Ronald Ralph Tuttle
Iii Clinton Eugene Browne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sicor Inc
Original Assignee
Sicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sicor Inc filed Critical Sicor Inc
Application granted granted Critical
Publication of ES2111973T3 publication Critical patent/ES2111973T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C07C45/305—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation with halogenochromate reagents, e.g. pyridinium chlorochromate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00—Surgery
    • Y10S128/13—Infusion monitoring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

SE PROPORCIONAN METODOS Y DISPOSITIVOS PARA DIAGNOSIS, EVALUACION Y TRATAMIENTO DE (CAD ENFERMEDAD DE ARTERIAS CORONARIAS) MEDIANTE UN SISTEMA DE ENTREGA DE FARMACOS DE BUCLE CERRADO, QUE ENTREGA UN AGENTE DE SIMULACION DE EJERCICIOS DE CATECOLAMINA, ALGUNOS DE LOS CUALES SON NUEVOS, QUE ORIGINAN RESPUESTAS TANTO AGUDAS COMO ADAPTABLES CARDIOVASCULARES, SIMILARES A LAS ORIGINADAS POR LA ACTIVIDAD AEROBICA. LAS RESPUESTAS AGUDAS AL AGENTE DE SIMULACION DE EJERCICIOS SE USAN PARA DIAGNOSTICAR Y EVALUAR LA CAD, EN VEZ DE LAS RESPUESTAS AGUDAS A EJERCICIO AEROBICO. DEBIDO A SUS RESPUESTAS ADAPTABLES, ESTOS COMPUESTOS PUEDEN USARSE PARA TRATAR LA CAD EN VEZ DE LAS RESPUESTAS ADAPTABLES ORIGINADAS POR EL ADIESTRAMIENTO DE EJERCICIO AEROBICO, O PARA TRATAR OTRAS SITUACIONES EN LAS QUE SON DESEABLES RESPUESTAS ADAPTABLES ORIGINADAS POR EL EJERCICIO AEROBICO.
ES95101920T 1988-02-19 1989-02-17 La diagnosis, la evaluacion, y el tratamiento de la enfermedad de la arteria coronaria mediante simulacion del ejercicio por la utilizacion de la administracion en ciclo cerrado de farmacos de un agente beta agonista que simula el ejercicio. Expired - Lifetime ES2111973T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15787588A 1988-02-19 1988-02-19
US07/308,683 US5108363A (en) 1988-02-19 1989-02-09 Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist

Publications (1)

Publication Number Publication Date
ES2111973T3 true ES2111973T3 (es) 1998-03-16

Family

ID=26854551

Family Applications (2)

Application Number Title Priority Date Filing Date
ES89301553T Expired - Lifetime ES2081299T3 (es) 1988-02-19 1989-02-17 Sistema para el suministro en ciclo cerrado de un agente simulador de ejercicio.
ES95101920T Expired - Lifetime ES2111973T3 (es) 1988-02-19 1989-02-17 La diagnosis, la evaluacion, y el tratamiento de la enfermedad de la arteria coronaria mediante simulacion del ejercicio por la utilizacion de la administracion en ciclo cerrado de farmacos de un agente beta agonista que simula el ejercicio.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES89301553T Expired - Lifetime ES2081299T3 (es) 1988-02-19 1989-02-17 Sistema para el suministro en ciclo cerrado de un agente simulador de ejercicio.

Country Status (13)

Country Link
US (4) US5108363A (es)
EP (2) EP0658538B1 (es)
JP (2) JP2806543B2 (es)
AT (2) ATE159710T1 (es)
AU (1) AU634152B2 (es)
DE (2) DE68924661T2 (es)
DK (1) DK73589A (es)
ES (2) ES2081299T3 (es)
FI (1) FI890776A7 (es)
GR (2) GR3018764T3 (es)
IE (2) IE80716B1 (es)
NO (1) NO890704L (es)
NZ (1) NZ239270A (es)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6144385A (ja) * 1984-08-07 1986-03-04 Tokyu Constr Co Ltd 構造物内の放射線吸収体の探査方法
IL82997A0 (en) * 1986-07-11 1987-12-20 Tanabe Seiyaku Co Method for epimerizing an optically active benzyl alcohol derivative
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
TW209832B (es) * 1989-10-10 1993-07-21 Glaxo Group Ltd
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
US5254087A (en) * 1990-01-29 1993-10-19 Ivra Systems, Inc. Tourniquet apparatus for intravenous regional anesthesia
US5556415A (en) * 1990-01-29 1996-09-17 Mcewen; James A. Physiologic tourniquet for intravenous regional anesthesia
US5607447A (en) * 1993-09-28 1997-03-04 Mcewen; James A. Physiologic tourniquet
US5281623A (en) * 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
AU3071992A (en) * 1991-11-13 1993-06-15 Gensia, Inc. Methods for increasing the sensitivity and decreasing the side effects of pharmacological stress testing for coronary artery disease
IL104365A0 (en) * 1992-01-31 1993-05-13 Gensia Pharma Method and apparatus for closed loop drug delivery
HUT64459A (en) * 1992-03-31 1994-01-28 Richter Gedeon Vegyeszet Process and apparatus for the diagnostics of cardiovascular
US5752521A (en) 1993-11-12 1998-05-19 Dardik; Irving I. Therapeutic exercise program
US6397098B1 (en) * 1994-09-21 2002-05-28 Medrad, Inc. Data communication and control for medical imaging systems
US5840026A (en) * 1994-09-21 1998-11-24 Medrad, Inc. Patient specific dosing contrast delivery systems and methods
US5551953A (en) * 1994-10-31 1996-09-03 Alza Corporation Electrotransport system with remote telemetry link
US7204848B1 (en) 1995-03-01 2007-04-17 Boston Scientific Scimed, Inc. Longitudinally flexible expandable stent
US5775329A (en) * 1995-06-07 1998-07-07 Gensia, Inc. Method and compounds for diagnosing coronary artery disease
US5855589A (en) * 1995-08-25 1999-01-05 Mcewen; James A. Physiologic tourniquet for intravenous regional anesthesia
US5931853A (en) * 1995-08-25 1999-08-03 Mcewen; James A. Physiologic tourniquet with safety circuit
US6430997B1 (en) * 1995-11-06 2002-08-13 Trazer Technologies, Inc. System and method for tracking and assessing movement skills in multidimensional space
EP0873293B1 (en) * 1995-12-22 2001-07-25 Abbott Laboratories Improved process for the preparation of alkyl or aryl aldehyde intermediates
US5874601A (en) * 1996-03-14 1999-02-23 Abbott Laboratories Process of protecting a 1,2-aminoalcohol for reductive amination coupling
US5706822A (en) * 1996-03-29 1998-01-13 Kozz Incorporated Method and computer program for creating individualized exercise protocols
US5711316A (en) * 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US5713923A (en) * 1996-05-13 1998-02-03 Medtronic, Inc. Techniques for treating epilepsy by brain stimulation and drug infusion
EP0947498B1 (en) * 1996-12-02 2004-09-15 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
US6018679A (en) * 1997-01-29 2000-01-25 Novartis Finance Corp. Iontophoretic transdermal delivery and control of adverse side-effects
CN1311877C (zh) 1998-06-03 2007-04-25 斯科特实验室公司 为患者缓解与内科或外科处理相关的痛苦的设备和方法
JP2002520101A (ja) * 1998-07-13 2002-07-09 ジェネトロニクス、インコーポレーテッド 電気的に補助される化粧用薬剤の局部送達法および装置
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
JP2002527401A (ja) * 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US6475514B1 (en) 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
US6361522B1 (en) * 1999-10-21 2002-03-26 Cardiac Pacemakers, Inc. Drug delivery system for implantable cardiac device
CZ20023818A3 (cs) 2000-05-18 2003-06-18 Alaris Meidical Systems, Inc. Systém a způsob pro správu informací týkajících se poskytování lékařské péče
US9427520B2 (en) 2005-02-11 2016-08-30 Carefusion 303, Inc. Management of pending medication orders
US9741001B2 (en) 2000-05-18 2017-08-22 Carefusion 303, Inc. Predictive medication safety
US9069887B2 (en) * 2000-05-18 2015-06-30 Carefusion 303, Inc. Patient-specific medication management system
US10353856B2 (en) 2011-03-17 2019-07-16 Carefusion 303, Inc. Scalable communication system
US11087873B2 (en) 2000-05-18 2021-08-10 Carefusion 303, Inc. Context-aware healthcare notification system
US10062457B2 (en) 2012-07-26 2018-08-28 Carefusion 303, Inc. Predictive notifications for adverse patient events
US7860583B2 (en) 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
EP1296595B1 (en) 2000-06-30 2007-08-15 Lifewaves International, Inc. System for assessing and modifying an individual's physiological condition
US7369890B2 (en) 2000-11-02 2008-05-06 Cardiac Pacemakers, Inc. Technique for discriminating between coordinated and uncoordinated cardiac rhythms
US6689117B2 (en) 2000-12-18 2004-02-10 Cardiac Pacemakers, Inc. Drug delivery system for implantable medical device
US7493162B2 (en) * 2001-06-15 2009-02-17 Cardiac Pacemakers, Inc. Pulmonary vein stent for treating atrial fibrillation
US7209783B2 (en) * 2001-06-15 2007-04-24 Cardiac Pacemakers, Inc. Ablation stent for treating atrial fibrillation
US7340303B2 (en) 2001-09-25 2008-03-04 Cardiac Pacemakers, Inc. Evoked response sensing for ischemia detection
AU2002350108B2 (en) * 2001-11-01 2008-09-11 Scott Laboratories, Inc. User interface for sedation and analgesia delivery systems and methods
US10173008B2 (en) 2002-01-29 2019-01-08 Baxter International Inc. System and method for communicating with a dialysis machine through a network
US8775196B2 (en) 2002-01-29 2014-07-08 Baxter International Inc. System and method for notification and escalation of medical data
US20030140928A1 (en) * 2002-01-29 2003-07-31 Tuan Bui Medical treatment verification system and method
US7236821B2 (en) * 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
CN101385738A (zh) * 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
US8234128B2 (en) 2002-04-30 2012-07-31 Baxter International, Inc. System and method for verifying medical device operational parameters
US20040172300A1 (en) * 2002-04-30 2004-09-02 Mihai Dan M. Method and system for integrating data flows
US20040176667A1 (en) * 2002-04-30 2004-09-09 Mihai Dan M. Method and system for medical device connectivity
US20040167804A1 (en) * 2002-04-30 2004-08-26 Simpson Thomas L.C. Medical data communication notification and messaging system and method
US20050065817A1 (en) * 2002-04-30 2005-03-24 Mihai Dan M. Separation of validated information and functions in a healthcare system
US20040172301A1 (en) * 2002-04-30 2004-09-02 Mihai Dan M. Remote multi-purpose user interface for a healthcare system
CA2490636A1 (en) * 2002-06-20 2003-12-31 The Governors Of The University Of Alberta Dichloroacetate in combination with cardioprotective or hemodynamic drugs
US7089055B2 (en) * 2002-06-28 2006-08-08 Cardiac Pacemakers, Inc. Method and apparatus for delivering pre-shock defibrillation therapy
EP1554003A4 (en) * 2002-10-03 2011-10-12 Scott Lab Inc SYSTEMS AND METHODS FOR TREND ANALYSIS IN AN SEDATION AND ANALYSIS SYSTEM
JP2006501899A (ja) 2002-10-03 2006-01-19 スコット・ラボラトリーズ・インコーポレイテッド センサ融合を提供するシステムおよび方法
US7072711B2 (en) 2002-11-12 2006-07-04 Cardiac Pacemakers, Inc. Implantable device for delivering cardiac drug therapy
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
GB0403864D0 (en) * 2004-02-20 2004-03-24 Ucl Ventures Modulator
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7567841B2 (en) 2004-08-20 2009-07-28 Cardiac Pacemakers, Inc. Method and apparatus for delivering combined electrical and drug therapies
EP1812101A4 (en) 2004-11-16 2014-04-23 Medrad Inc MODELING PHARMACEUTICAL DISSIPATION
DK2902053T3 (da) * 2004-11-24 2017-11-13 Bayer Healthcare Llc Anordninger, systemer og fremgangsmåder til væskefremføring
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7616990B2 (en) 2005-10-24 2009-11-10 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US8182443B1 (en) 2006-01-17 2012-05-22 Masimo Corporation Drug administration controller
WO2007087505A2 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2097835B1 (en) 2006-12-29 2018-05-30 Bayer Healthcare LLC Patient-based parameter generation systems for medical injection procedures
US9351947B2 (en) * 2007-01-29 2016-05-31 National Research Council Of Canada Use of catecholamines and related compounds as anti-angiogenic agents
EP2170165B1 (en) 2007-07-17 2018-12-05 Bayer Healthcare LLC Systems for determination of parameters for a procedure, for estimation of cardiopulmonary function and for fluid delivery
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation
US10089443B2 (en) 2012-05-15 2018-10-02 Baxter International Inc. Home medical device systems and methods for therapy prescription and tracking, servicing and inventory
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
US8554579B2 (en) 2008-10-13 2013-10-08 Fht, Inc. Management, reporting and benchmarking of medication preparation
US9421330B2 (en) * 2008-11-03 2016-08-23 Bayer Healthcare Llc Mitigation of contrast-induced nephropathy
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20110137297A1 (en) * 2009-09-17 2011-06-09 Kiani Massi Joe E Pharmacological management system
CA2803169C (en) 2010-06-24 2020-09-22 Medrad, Inc. Modeling of pharmaceutical propagation and parameter generation for injection protocols
HUE056182T2 (hu) 2012-05-14 2022-01-28 Bayer Healthcare Llc Összeállítások és eljárások gyógyászati fluidum befecskendezési protokollok röntgencsõ-feszültség alapján történõ meghatározására
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US8761717B1 (en) 2012-08-07 2014-06-24 Brian K. Buchheit Safety feature to disable an electronic device when a wireless implantable medical device (IMD) is proximate
KR102029974B1 (ko) 2012-08-31 2019-10-08 백스터 코포레이션 잉글우드 약제 요청서 집행 시스템 및 방법
EP3453377B1 (en) 2012-10-26 2026-04-29 Baxter Corporation Englewood Improved work station for medical dose preparation system
KR101695119B1 (ko) 2012-10-26 2017-01-23 백스터 코포레이션 잉글우드 의료 투여분 조제 시스템을 위한 개선된 이미지 취득
US11182728B2 (en) 2013-01-30 2021-11-23 Carefusion 303, Inc. Medication workflow management
US10430554B2 (en) 2013-05-23 2019-10-01 Carefusion 303, Inc. Medication preparation queue
WO2014190200A1 (en) 2013-05-22 2014-11-27 Carefusion 303, Inc. Medication workflow management
US9946844B2 (en) * 2013-02-22 2018-04-17 Cloud Dx, Inc. Systems and methods for monitoring patient medication adherence
US9555379B2 (en) 2013-03-13 2017-01-31 Bayer Healthcare Llc Fluid path set with turbulent mixing chamber, backflow compensator
ES2831801T3 (es) 2013-03-13 2021-06-09 Carefusion 303 Inc Sistema de gestión de medicaciones específicas para el paciente
CN114267429A (zh) 2013-03-13 2022-04-01 康尔福盛303公司 预测性用药安全
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
JP2017525032A (ja) 2014-06-30 2017-08-31 バクスター・コーポレーション・イングルウッドＢａｘｔｅｒ Ｃｏｒｐｏｒａｔｉｏｎ Ｅｎｇｌｅｗｏｏｄ 管理された医療情報交換
US11575673B2 (en) 2014-09-30 2023-02-07 Baxter Corporation Englewood Central user management in a distributed healthcare information management system
US11107574B2 (en) 2014-09-30 2021-08-31 Baxter Corporation Englewood Management of medication preparation with formulary management
EP3210183B1 (en) 2014-10-24 2020-09-02 Baxter Corporation Englewood Automated exchange of healthcare information for fulfillment of medication doses
EP3937116A1 (en) 2014-12-05 2022-01-12 Baxter Corporation Englewood Dose preparation data analytics
CA2978455A1 (en) 2015-03-03 2016-09-09 Baxter Corporation Englewood Pharmacy workflow management with integrated alerts
EP3314488B1 (en) 2015-06-25 2024-03-13 Gambro Lundia AB Medical device system and method having a distributed database
EP3423130B1 (en) 2016-03-03 2025-05-14 Bayer Healthcare LLC System and method for improved fluid delivery in multi-fluid injector systems
EP3538182A1 (en) 2016-11-14 2019-09-18 Bayer Healthcare LLC Methods and systems for verifying the contents of a syringe used for medical fluid delivery
KR102476516B1 (ko) 2016-12-21 2022-12-09 감브로 룬디아 아베 외부 도메인을 지원하는 안전한 클러스터 도메인을 구비한 정보 기술 인프라를 포함하는 의료 장치 시스템
CN110891630B (zh) 2017-08-31 2022-04-26 拜耳医药保健有限公司 驱动构件定位和流体注入器系统机械校准的系统和方法
CN110809482B (zh) 2017-08-31 2023-03-07 拜耳医药保健有限公司 流体注入器系统体积补偿系统和方法
JP7493337B2 (ja) 2017-08-31 2024-05-31 バイエル・ヘルスケア・エルエルシー 流体インジェクタシステムにおける動的圧力制御のための方法
AU2018326485B2 (en) 2017-08-31 2024-01-04 Bayer Healthcare Llc Injector pressure calibration system and method
AU2018323442B2 (en) 2017-08-31 2024-06-27 Bayer Healthcare Llc Fluid path impedance assessment for improving fluid delivery performance
CA3097557A1 (en) 2018-04-19 2019-10-24 Bayer Healthcare Llc System and method for air detection in fluid injector
CA3110859A1 (en) 2018-08-28 2020-03-05 Bayer Healthcare Llc Fluid injector system, method of preventing fluid backflow, and computer program product
JP2021536278A (ja) 2018-08-28 2021-12-27 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC 比性能を改善した流体注入器システム
US12138425B2 (en) 2019-05-21 2024-11-12 Tandem Diabetes Care, Inc. System and method for incorporating exercise into closed-loop diabetes therapy
US11969576B2 (en) 2019-07-03 2024-04-30 Tandem Diabetes Care, Inc. Methods of incorporating CGM data into diabetes therapy
US12564677B2 (en) 2019-10-21 2026-03-03 Tandem Diabetes Care, Inc. Systems and methods for automated insulin delivery response to inaccurate or missed glucose values
US11654236B2 (en) 2019-11-22 2023-05-23 Tandem Diabetes Care, Inc. Systems and methods for automated insulin delivery for diabetes therapy
US11911595B2 (en) 2020-05-18 2024-02-27 Tandem Diabetes Care, Inc. Systems and methods for automated insulin delivery response to meal announcements

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA570892A (en) * 1959-02-17 D. Moed Hendrik Method of producing substituted aralkyl-, phenyl-, alkylamines
DE1144291B (de) * 1957-11-05 1963-02-28 Philips Nv Verfahren zur Herstellung einer optisch-aktiven broncholytisch wirksamen Verbindung
US3135797A (en) * 1958-04-15 1964-06-02 Colgate Palmolive Co Aromatic amino antispasmodic compounds
US3319623A (en) * 1964-07-13 1967-05-16 Seymour B London Blood pressure monitors
US3969410A (en) * 1972-01-12 1976-07-13 Boehringer Ingelheim Gmbh 1-(2'-Alkyl-3',4'-dihydroxy-phenyl)-2-(phenylalkyl-amino)-alkanols-(1) and salts thereof
FR1541394A (fr) 1966-10-18 1968-10-04 Boehringer Sohn Ingelheim Procédé de fabrication de nouvelles 3, 4-dihydroxyphénylalcanolamines
US3803320A (en) * 1968-07-24 1974-04-09 Geigy Chem Corp Control of insects,acarinae and nematodes with basically substituted 1-cyano-o-carbamoyl-formoximes
US3803230A (en) * 1969-05-30 1974-04-09 Allen & Hanburys Ltd 5-(2-((1-methyl-3-phenylpropyl)amino)ethyl)salicylamide hydrochloride
US3651806A (en) * 1969-10-24 1972-03-28 Philip I Hirshberg Method and apparatus for administering digitalizing medications
GB1301134A (en) * 1970-07-18 1972-12-29 Pfizer Ltd SUBSTITUTED 1-PHENYL-2-ALLYLAMINO-ALKANOLS, 1-PHENYL-2-ALLYLAMINO-ALKANES AND alpha-AMINOALKYLPHENYL KETONES
US4086272A (en) * 1970-07-18 1978-04-25 Pfizer Inc. Phenyl-alkanolamine, alkylamine and alpha-aminoalkyl ketone derivatives as heart stimulants
NL7112938A (es) * 1970-09-30 1972-04-05
US3987200A (en) * 1972-04-12 1976-10-19 Eli Lilly And Company Method for increasing cardiac contractility
JPS5310582B2 (es) * 1973-04-28 1978-04-14
FR2328456A1 (fr) * 1975-10-22 1977-05-20 Bruneau & Cie Lab Derives de phenylethanolamine, leur preparation et leur application en therapeutique
US4080966A (en) * 1976-08-12 1978-03-28 Trustees Of The University Of Pennsylvania Automated infusion apparatus for blood pressure control and method
US4141359A (en) * 1976-08-16 1979-02-27 University Of Utah Epidermal iontophoresis device
US4078562A (en) * 1976-08-16 1978-03-14 Diana W. Friedman Infusion pump with feedback control
SE402569B (sv) * 1976-11-09 1978-07-10 Aga Ab Anordning vid en andningsapparat for dykare
DD144050A5 (de) * 1978-06-05 1980-09-24 Ciba Geigy Ag Verfahren zur herstellung von n-alkylierten aminoalkoholen
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
DK269079A (da) * 1978-07-03 1980-02-01 Lilly Co Eli Fremgangsmaade til fremstilling af phenethanolaminer
US4845127A (en) * 1978-07-03 1989-07-04 Eli Lilly And Company Phenethanolamines, compositions containing the same and method for effecting weight control
ATE1899T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
US4280494A (en) * 1979-06-26 1981-07-28 Cosgrove Robert J Jun System for automatic feedback-controlled administration of drugs
US4392849A (en) * 1981-07-27 1983-07-12 The Cleveland Clinic Foundation Infusion pump controller
IL70813A (en) * 1983-01-31 1987-10-30 Lilly Co Eli Animal feed comprising certain phenethanolamine derivatives and 1-phenyl-2-(1-methyl-3-(4-nitrophenyl)propylamino)ethanol hydrochloride
US4837305A (en) * 1983-02-03 1989-06-06 The Regents Of The University Of California Derivatives of β-adrenergic antagonists
US5135479A (en) * 1983-08-18 1992-08-04 Drug Delivery Systems, Inc. Programmable control and mounting system for transdermal drug applicator
EP0135905A3 (de) * 1983-09-29 1986-10-22 ASTA Pharma Aktiengesellschaft Neue 1-(Alkyl-hydroxy-phenyl)-1-hydroxy-2-(alkylamino)-propane
US4562206A (en) * 1983-12-23 1985-12-31 Key Pharmaceuticals, Inc. Orally effective inotropic compounds
US4828545A (en) * 1984-02-08 1989-05-09 Omni-Flow, Inc. Pressure responsive multiple input infusion system
CA1254091A (en) * 1984-09-28 1989-05-16 Vladimir Feingold Implantable medication infusion system
US5088981A (en) * 1985-01-18 1992-02-18 Howson David C Safety enhanced device and method for effecting application of a therapeutic agent
BR8507219A (pt) * 1985-06-10 1987-08-04 Drug Delivery Systems Inc Sistema de montagem e controle programavel para aplicador de droga transdermico
US4688577A (en) * 1986-02-10 1987-08-25 Bro William J Apparatus for and method of monitoring and controlling body-function parameters during intracranial observation
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
EP0313638A4 (en) * 1987-05-15 1989-06-14 Martin H Newman IONTOPHORESIS INOPHORESIS DRUG ADMINISTRATION SYSTEM.
US4931046A (en) * 1987-05-15 1990-06-05 Newman Martin H Iontophoresis drug delivery system
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US4846792A (en) * 1988-03-08 1989-07-11 Baxter International Inc. Automatic infiltration detection system and method

Also Published As

Publication number Publication date
DE68924661T2 (de) 1996-03-21
NZ239270A (en) 1993-10-26
IE71651B1 (en) 1997-02-26
JPH10276991A (ja) 1998-10-20
FI890776A0 (fi) 1989-02-17
US5286252A (en) 1994-02-15
AU634152B2 (en) 1993-02-18
EP0329464B1 (en) 1995-11-02
GR3018764T3 (en) 1996-04-30
EP0658538A1 (en) 1995-06-21
IE960742L (en) 1989-08-19
US5460605A (en) 1995-10-24
EP0329464A3 (en) 1991-07-17
DE68924661D1 (de) 1995-12-07
GR3025892T3 (en) 1998-04-30
JP2806543B2 (ja) 1998-09-30
IE890526L (en) 1989-08-19
EP0658538B1 (en) 1997-10-29
ATE129644T1 (de) 1995-11-15
EP0329464A2 (en) 1989-08-23
DK73589D0 (da) 1989-02-17
AU3008889A (en) 1989-08-24
US5395970A (en) 1995-03-07
NO890704L (no) 1989-08-21
JPH0217048A (ja) 1990-01-22
NO890704D0 (no) 1989-02-20
US5108363A (en) 1992-04-28
ATE159710T1 (de) 1997-11-15
ES2081299T3 (es) 1996-03-01
DK73589A (da) 1989-08-20
DE68928422D1 (de) 1997-12-04
DE68928422T2 (de) 1998-02-26
FI890776A7 (fi) 1989-08-20
IE80716B1 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
ES2111973T3 (es) La diagnosis, la evaluacion, y el tratamiento de la enfermedad de la arteria coronaria mediante simulacion del ejercicio por la utilizacion de la administracion en ciclo cerrado de farmacos de un agente beta agonista que simula el ejercicio.
Fertel-Daly et al. Effects of a weighted vest on attention to task and self-stimulatory behaviors in preschoolers with pervasive developmental disorders
Twining Mental practice and physical practice in learning a motor skill
Steward et al. Do doctors know what children know?
Rentz et al. Active-imaginal exposure: Examination of a new behavioral treatment for cynophobia (dog phobia)
Conley et al. Treatment by overcorrection of self-injurious eye gouging in preschool blind children
MdYusof et al. Dolphin Encounter for Special Children (DESC) Program: Effectiveness of Dolphin-Assisted Therapy for Children with Autism.
Masterson et al. The role of proprioceptive stimulus change in the rat’s avoidance learning
Bruning et al. The Impact of Various Stress Management Training Strategies A Longitudinal Field Experiment.
DeCasper et al. Steady-state behavior in children: A method and some data
Berube Survival camping: A therapeutic modality.
Cade Cancer: the patient's viewpoint and the clinician's problems
Baras Effect of mode of presentation on semantic satiation
Dion et al. A rehabilitation model for persons with bipolar disorder.
Anđelić et al. From an idea to its realization: A new training centre at the institute for emergency medicine Belgrade
Keehn Translating behavioral research into practical terms for alcoholism.
Culliton Kennedy hearings: Year-long probe of biomedical research begins
Walker Some reflection on the death of Dr. Martin Luther King--a commentary on white racism
Skottowe Teaching psychiatry in mental hospitals
Sullivan AN APPLICATION OF SOCIAL LEARNING THEORY TO GROUP MARITAL THERAPY.
Levine et al. Dye, Joseph A.
Meyers Reform in Medical-Education
Roberts Schreber as machine, technophobe, and virtualist.
DeVita Treatment of Hodgkin's disease in private practice
Teoh et al. Short-term psychotherapy by medical students–its therapeutic effectiveness and its educational value

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 658538

Country of ref document: ES